NASDAQ:TMDX TransMedics Group (TMDX) Stock Forecast, Price & News $79.40 +4.64 (+6.21%) (As of 06/6/2023 ET) Add Compare Share Share Today's Range$74.47▼$80.1850-Day Range$66.23▼$88.7352-Week Range$24.01▼$90.15Volume1.13 million shsAverage Volume533,362 shsMarket Capitalization$2.58 billionP/E RatioN/ADividend YieldN/APrice Target$72.29 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media TransMedics Group MarketRank™ ForecastAnalyst RatingModerate Buy2.86 Rating ScoreUpside/Downside9.0% Downside$72.29 Price TargetShort InterestBearish10.14% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.58Based on 5 Articles This WeekInsider TradingSelling Shares$2.56 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.62) to ($0.01) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.23 out of 5 starsMedical Sector947th out of 981 stocksElectromedical Equipment Industry20th out of 21 stocks 1.4 Analyst's Opinion Consensus RatingTransMedics Group has received a consensus rating of Buy. The company's average rating score is 2.86, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $72.29, TransMedics Group has a forecasted downside of 9.0% from its current price of $79.40.Amount of Analyst CoverageTransMedics Group has received no research coverage in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted10.14% of the outstanding shares of TransMedics Group have been sold short.Short Interest Ratio / Days to CoverTransMedics Group has a short interest ratio ("days to cover") of 5.2.Change versus previous monthShort interest in TransMedics Group has recently increased by 35.25%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldTransMedics Group does not currently pay a dividend.Dividend GrowthTransMedics Group does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TMDX. Previous Next 2.0 News and Social Media Coverage News SentimentTransMedics Group has a news sentiment score of 0.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for TransMedics Group this week, compared to 3 articles on an average week.Search InterestOnly 4 people have searched for TMDX on MarketBeat in the last 30 days. This is a decrease of -78% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added TransMedics Group to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, TransMedics Group insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,556,128.00 in company stock.Percentage Held by InsidersOnly 6.70% of the stock of TransMedics Group is held by insiders.Percentage Held by Institutions88.58% of the stock of TransMedics Group is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for TransMedics Group are expected to grow in the coming year, from ($0.62) to ($0.01) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of TransMedics Group is -83.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of TransMedics Group is -83.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTransMedics Group has a P/B Ratio of 13.53. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About TransMedics Group (NASDAQ:TMDX) StockTransMedics Group, Inc. operates as a commercial stage medical technology company. The firm engages in the development and commercialization of organ care system platform. It focuses on the preservation of human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation. The company was founded by Waleed H. Hassanein in August 1998 and is headquartered in Andover, MA.Read More Receive TMDX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for TransMedics Group and its competitors with MarketBeat's FREE daily newsletter. Email Address TMDX Stock News HeadlinesJune 3, 2023 | americanbankingnews.comBrokerages Set TransMedics Group, Inc. (NASDAQ:TMDX) Price Target at $72.29May 26, 2023 | finance.yahoo.comTransMedics Group, Inc.'s (NASDAQ:TMDX) P/S Still Appears To Be ReasonableJune 6, 2023 | Behind the Markets (Ad)Laser breakthrough could send stock soaring 2,467%Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...May 20, 2023 | seekingalpha.comTransMedics: Expensive, But High PotentialMay 11, 2023 | americanbankingnews.comTransMedics Group (NASDAQ:TMDX) Sees Large Volume IncreaseMay 10, 2023 | seekingalpha.comTransMedics upsizes and prices $400M senior convertible notesMay 10, 2023 | americanbankingnews.comTransMedics Group (NASDAQ:TMDX) Shares Gap Down to $74.02May 9, 2023 | msn.comTransMedics prices and upsizes $400M senior convertible notesJune 6, 2023 | Legacy Research (Affiliate) (Ad)From -60% Account to Doubling His Money?After helping his readers double their money 13 TIMES in the last year alone… There’s ONE person trader Jeff Clark has NOT been able to help! His 23-year-old son, Grant.May 9, 2023 | finance.yahoo.comTransMedics Group, Inc. Prices $400 Million of Convertible Senior Notes Due 2028May 8, 2023 | finance.yahoo.comTransMedics Group, Inc. Announces Proposed Offering of $300 Million of Convertible Senior Notes Due 2028May 7, 2023 | americanbankingnews.comBrokerages Set TransMedics Group, Inc. (NASDAQ:TMDX) Target Price at $72.29May 6, 2023 | finance.yahoo.comRainbows and Unicorns: TransMedics Group, Inc. (NASDAQ:TMDX) Analysts Just Became A Lot More OptimisticMay 5, 2023 | finance.yahoo.comIs TransMedics Group Stock a Buy on the Dip?May 5, 2023 | americanbankingnews.comTransMedics Group, Inc. (NASDAQ:TMDX) CFO Sells $395,250.00 in StockMay 4, 2023 | finance.yahoo.comTransMedics Group, Inc. (NASDAQ:TMDX) Q1 2023 Earnings Call TranscriptMay 4, 2023 | americanbankingnews.comWaleed H. Hassanein Sells 7,500 Shares of TransMedics Group, Inc. (NASDAQ:TMDX) StockMay 4, 2023 | americanbankingnews.comOppenheimer Increases TransMedics Group (NASDAQ:TMDX) Price Target to $90.00May 3, 2023 | msn.comMorgan Stanley Maintains Transmedics Group (TMDX) Equal-Weight RecommendationMay 2, 2023 | msn.comOppenheimer Maintains Transmedics Group (TMDX) Outperform RecommendationMay 2, 2023 | finance.yahoo.comQ1 2023 Transmedics Group Inc Earnings CallMay 1, 2023 | markets.businessinsider.comTransMedics Reports First Quarter 2023 Financial ResultsMay 1, 2023 | finance.yahoo.comTransMedics Releases Inaugural Environmental, Social & Governance (ESG) ReportApril 30, 2023 | americanbankingnews.comShort Interest in TransMedics Group, Inc. (NASDAQ:TMDX) Grows By 16.8%April 29, 2023 | americanbankingnews.comTransMedics Group (TMDX) Set to Announce Quarterly Earnings on MondayApril 28, 2023 | americanbankingnews.comTransMedics Group, Inc. (NASDAQ:TMDX) Insider Sells $1,037,603.28 in StockApril 27, 2023 | finance.yahoo.comTransMedics Group (NASDAQ:TMDX) shareholder returns have been enviable, earning 340% in 3 yearsSee More Headlines TMDX Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TMDX Company Calendar Last Earnings5/01/2023Today6/06/2023Next Earnings (Estimated)8/07/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Electromedical equipment Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:TMDX CUSIPN/A CIK1756262 Webwww.transmedics.com Phone(978) 552-0900FaxN/AEmployees148Year FoundedN/APrice Target and Rating Average Stock Price Forecast$72.29 High Stock Price Forecast$90.00 Low Stock Price Forecast$45.00 Forecasted Upside/Downside-9.4%Consensus RatingModerate Buy Rating Score (0-4)2.86 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($0.95) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-36,230,000.00 Net Margins-23.76% Pretax Margin-23.70% Return on Equity-18.30% Return on Assets-11.84% Debt Debt-to-Equity Ratio0.31 Current Ratio9.14 Quick Ratio8.30 Sales & Book Value Annual Sales$93.46 million Price / Sales27.78 Cash FlowN/A Price / Cash FlowN/A Book Value$5.87 per share Price / Book13.59Miscellaneous Outstanding Shares32,550,000Free Float30,373,000Market Cap$2.60 billion OptionableNot Optionable Beta1.45 Key ExecutivesWaleed H. HassaneinPresident, Chief Executive Officer & DirectorJohn F. CareyVice President-OperationsStephen GordonChief Financial Officer, Secretary & TreasurerMark AndersonSenior Director-Technology DevelopmentPhillip CampChief Medical OfficerKey CompetitorsLivaNovaNASDAQ:LIVNInModeNASDAQ:INMDIntegerNYSE:ITGRCONMEDNYSE:CNMDOutset MedicalNASDAQ:OMView All CompetitorsInsiders & InstitutionsWaleed H HassaneinSold 7,500 sharesTotal: $537,300.00 ($71.64/share)ProShare Advisors LLCSold 335 shares on 5/26/2023Ownership: 0.011%Ameriprise Financial Inc.Bought 12,740 shares on 5/22/2023Ownership: 0.429%Putnam Investments LLCSold 9,695 shares on 5/22/2023Ownership: 0.083%JPMorgan Chase & Co.Bought 67,753 shares on 5/18/2023Ownership: 0.306%View All Insider TransactionsView All Institutional Transactions TMDX Stock - Frequently Asked Questions Should I buy or sell TransMedics Group stock right now? 7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for TransMedics Group in the last year. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" TMDX shares. View TMDX analyst ratings or view top-rated stocks. What is TransMedics Group's stock price forecast for 2023? 7 Wall Street analysts have issued 12 month price objectives for TransMedics Group's shares. Their TMDX share price forecasts range from $45.00 to $90.00. On average, they predict the company's stock price to reach $72.29 in the next year. This suggests that the stock has a possible downside of 9.4%. View analysts price targets for TMDX or view top-rated stocks among Wall Street analysts. How have TMDX shares performed in 2023? TransMedics Group's stock was trading at $61.72 at the beginning of 2023. Since then, TMDX stock has increased by 29.2% and is now trading at $79.77. View the best growth stocks for 2023 here. Are investors shorting TransMedics Group? TransMedics Group saw a increase in short interest in May. As of May 15th, there was short interest totaling 3,300,000 shares, an increase of 35.2% from the April 30th total of 2,440,000 shares. Based on an average daily trading volume, of 635,600 shares, the days-to-cover ratio is presently 5.2 days. View TransMedics Group's Short Interest. When is TransMedics Group's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 7th 2023. View our TMDX earnings forecast. How were TransMedics Group's earnings last quarter? TransMedics Group, Inc. (NASDAQ:TMDX) released its quarterly earnings data on Monday, May, 1st. The company reported ($0.08) EPS for the quarter, topping the consensus estimate of ($0.25) by $0.17. The firm had revenue of $41.60 million for the quarter, compared to the consensus estimate of $36.05 million. TransMedics Group had a negative net margin of 23.76% and a negative trailing twelve-month return on equity of 18.30%. The firm's revenue was up 161.6% compared to the same quarter last year. During the same quarter last year, the business earned ($0.38) earnings per share. What ETFs hold TransMedics Group's stock? ETFs with the largest weight of TransMedics Group (NASDAQ:TMDX) stock in their portfolio include Changebridge Select Equity ETF (CBSE), Changebridge Long/Short Equity ETF (CBLS), Invesco DWA Healthcare Momentum ETF (PTH), Alger 35 ETF (ATFV), SPDR S&P Health Care Equipment ETF (XHE), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), Invesco DWA SmallCap Momentum ETF (DWAS) and Principal Healthcare Innovators ETF (BTEC). What guidance has TransMedics Group issued on next quarter's earnings? TransMedics Group issued an update on its FY 2023 earnings guidance on Monday, May, 1st. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $160.00 million-$170.00 million, compared to the consensus revenue estimate of $157.66 million. What is Waleed Hassanein's approval rating as TransMedics Group's CEO? 17 employees have rated TransMedics Group Chief Executive Officer Waleed Hassanein on Glassdoor.com. Waleed Hassanein has an approval rating of 83% among the company's employees. What other stocks do shareholders of TransMedics Group own? Based on aggregate information from My MarketBeat watchlists, some companies that other TransMedics Group investors own include Advanced Micro Devices (AMD), Roku (ROKU), AbbVie (ABBV), Gilead Sciences (GILD), Pfizer (PFE), Raytheon Technologies (RTX), Yamana Gold (AUY), B2Gold (BTG), Beyond Meat (BYND) and Walt Disney (DIS). When did TransMedics Group IPO? (TMDX) raised $75 million in an initial public offering (IPO) on Thursday, May 2nd 2019. The company issued 4,700,000 shares at a price of $15.00-$17.00 per share. Morgan Stanley and J.P. Morgan acted as the underwriters for the IPO and Cowen and Company and Canaccord Genuity were co-managers. What is TransMedics Group's stock symbol? TransMedics Group trades on the NASDAQ under the ticker symbol "TMDX." Who are TransMedics Group's major shareholders? TransMedics Group's stock is owned by a number of retail and institutional investors. Top institutional shareholders include FMR LLC (10.00%), BlackRock Inc. (6.93%), Macquarie Group Ltd. (5.36%), Fred Alger Management LLC (3.51%), Allspring Global Investments Holdings LLC (2.94%) and Credit Suisse AG (2.53%). Insiders that own company stock include Abrams Capital Management, LP, David Weill, Edward M Basile, Edwin M Kania Jr, James R Tobin, John F Carey, John F Carey, John F Sullivan, Laura Damme, Miriam Provost, Stephanie Lovell, Stephen Gordon, Tamer I Khayal, Tamer I Khayal and Waleed H Hassanein. View institutional ownership trends. How do I buy shares of TransMedics Group? Shares of TMDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is TransMedics Group's stock price today? One share of TMDX stock can currently be purchased for approximately $79.77. How much money does TransMedics Group make? TransMedics Group (NASDAQ:TMDX) has a market capitalization of $2.60 billion and generates $93.46 million in revenue each year. The company earns $-36,230,000.00 in net income (profit) each year or ($0.95) on an earnings per share basis. How many employees does TransMedics Group have? The company employs 148 workers across the globe. How can I contact TransMedics Group? TransMedics Group's mailing address is 200 MINUTEMAN ROAD SUITE 302, ANDOVER MA, 01810. The official website for the company is www.transmedics.com. The company can be reached via phone at (978) 552-0900 or via email at investors@transmedics.com. This page (NASDAQ:TMDX) was last updated on 6/6/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TransMedics Group, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.